2001, 2013, Clinical Trials and Concentrates

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2001

2013

Clinical Trials

Concentrates

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 2013 Sep;36(9):2530-5.

Extraction

Extraction Pharmaceutical CBD Epilepsy

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

NOVEMBER 24, 2021

Only one article appeared in the MJA in 2000 and again in 2001. Legitimacy framings occur in at least three articles a year between 2013 and 2018 and are most predominant in 2014 and 2019 with a total of five articles in those years. MJA, 16 December 2013). There was one case study and one book review during this period.

Research and Development

Research and Development Medicine Access Media

Medical Cannabis Brief

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Stay Connected